Diskusjon Triggere Porteføljer AksjonærlisterNy!

Frequencytx

Investeringer: #<Tag:0x00007eff23a4b428>

Frequencytx.com er eit spennende firma som kom på børs i oktober 2019 og har gått 100 % siden den gang.
Dem er inni en phase 2 a på medisinen fx322 som skal reversere hørselen.

The human ear does not spontaneously restore lost or damaged hair cells, making hearing loss a permanent condition. Today, there are no FDA-approved therapeutic options for SNHL.

FX-322 is designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating hair cells through activation of progenitor cells already present in the cochlea.

In a Phase 1/2 study, FX-322 demonstrated a statistically significant and clinically meaningful improvement in key measures of hearing loss, including clarity of sound and word understanding. In addition, FX-322 was observed to be well-tolerated with no serious adverse effects. FX-322 is administered locally by an ear, nose, and throat specialist, using a standard in-office procedure.

In 4Q 2019 we commenced a Phase 2a study of FX-322.